Evaluation of the European Society of Cardiology (ESC) risk assessment score in incident systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).
Zoe R BrownDylan HansenWendy StevensNava FerdowsiLaura J RossAlannah QuinlivanJoanne SahharGene-Siew NgianDiane ApostolopoulosJennifer G WalkerSusanna ProudmanGim Gee TengAndrea Hl LowKathleen MorrisroeMandana NikpourPublished in: Arthritis care & research (2024)
The 2022 ESC risk assessment strategy applied at baseline and follow up predicts survival in SSc-PAH. Treatment decisions for SSc-PAH should include risk assessments, aiming to achieve low risk status according to the 2022 ESC guidelines.
Keyphrases
- systemic sclerosis
- pulmonary arterial hypertension
- risk assessment
- interstitial lung disease
- polycyclic aromatic hydrocarbons
- pulmonary artery
- human health
- pulmonary hypertension
- heavy metals
- cardiovascular disease
- clinical practice
- cardiac surgery
- rheumatoid arthritis
- coronary artery
- combination therapy
- idiopathic pulmonary fibrosis
- replacement therapy
- climate change